Stocks
Instil Bio, Inc.TIL
NASDAQHealthcareBiotechnology$5.70
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing novel T cell receptor-based therapies for solid tumors. Its lead candidate, ITIL-306, is an autologous tumor-infiltrating lymphocyte therapy in early-stage trials for non-small cell lung cancer. Investors track the stock for its potential in the adoptive cell therapy space, though the company has faced clinical setbacks and a strategic pivot.
52W Range: $5.62-$20.11
Congressional Interest in Instil Bio, Inc. (TIL)
No congressional trades have been disclosed for Instil Bio, Inc. (TIL) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading TIL?
No congressional trades found for this stock.